home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
DP Tool Club 17
/
CD_ASCQ_17_101194.iso
/
vrac
/
med9408d.zip
/
M9480660.TXT
< prev
next >
Wrap
Text File
|
1994-08-27
|
3KB
|
44 lines
Document 0660
DOCN M9480660
TI Emerging indications for octreotide therapy, Part 1.
DT 9410
AU Mosdell KW; Visconti JA; Raabe College of Pharmacy, Ohio Northern
University.
SO Am J Hosp Pharm. 1994 May 1;51(9):1184-92. Unique Identifier : AIDSLINE
MED/94317668
AB Possible new indications for the use of octreotide are discussed. In
October 1988, octreotide received FDA-approved labeling for use in the
management of carcinoid syndrome and vipomas. Since that time, research
results and clinical experience have accumulated that suggest a
potentially much broader therapeutic role for octreotide. Reports
continue to be published on the use of octreotide for treating pituitary
tumors, gastroenteropancreatic tumors, diabetes mellitus,
AIDS-associated diarrhea, autonomic neuropathy, pancreatitis, pancreatic
pseudocysts and ascites, complications of pancreatic surgery and
transplantation, ileostomy-associated diarrhea, enterocutaneous
fistulas, pancreatic fistulas, dumping syndrome, short bowel syndrome,
and gastrointestinal bleeding. Other emerging indications for the use of
octreotide include psoriasis, hypercalcemia, cancer-related pain,
polycystic ovary syndrome, and certain cancers. In children, octreotide
has been studied for use in treating hyperinsulinemic hypoglycemia of
infancy. Along with the common adverse effects of octreotide, such as
pain at the injection site and nausea, less frequent effects, such as
cholelithiasis, gallbladder hypercontractility, and gastritis have now
been described. Much of what has been learned is based on small
uncontrolled studies and case reports, since the rarity of many of the
conditions for which octreotide has shown promise has tended to preclude
larger studies. As clinical experience with octreotide accumulates and
better-designed trials are completed where possible, a broader
therapeutic role for octreotide is likely to be recognized.
DE Acquired Immunodeficiency Syndrome/COMPLICATIONS Acromegaly/DRUG
THERAPY Diabetes Mellitus/COMPLICATIONS/DRUG THERAPY Diarrhea/DRUG
THERAPY/ETIOLOGY Digestive System Neoplasms/DRUG THERAPY Human
Malignant Carcinoid Syndrome/DRUG THERAPY
Octreotide/PHARMACOLOGY/*THERAPEUTIC USE Pituitary Neoplasms/DRUG
THERAPY Randomized Controlled Trials Support, Non-U.S. Gov't JOURNAL
ARTICLE REVIEW REVIEW, TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).